Ginkgo Bioworks Holdings Inc vs iShares Global Tech ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.46 (market cap $505.73M), while iShares Global Tech ETF trades at $142.44. The key difference: iShares Global Tech ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | IXN | |
|---|---|---|
Market Cap | $505.73M | — |
Sector | Health | Sector/Thematic |
52-Week High | $16.14 | $149.74 |
52-Week Low | $5.48 | $94.42 |
Enterprise Value | $607.68M | — |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
No Aura AI signal available yet.
Trailing returns across standard periods
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →